A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Clinical trial NCT04639180 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04639180
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-01
- Primary completion
- 2026-07-31
- Enrollment
- 687
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.